1. In Vivo

China Drug Price Negotiations: Another Race To The Bottom？

Competition, Coverage and Cost Control

 
• By Brian Yang

With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?

CHINA DRUG PRICE NEGOTIATIONS: ANOTHER RACE TO BOTTOM?
2011 CHINA DRUG PRICE NEGOTIATIONS COULD BECOME ANOTHER RACE TO BOTTOM • Source: Shutterstock

As China’s annual drug reimbursement talks kick into high gear and enter the final key stage before formal discussions, many will be watching for any signs of unusually aggressive price-cutting this year. Many fear another race to the bottom for pharma companies large or small, domestic or international.

This would be along the lines of what happened in 2021, during which the price of an innovative rare disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.